Spero Therapeutics Inc Asset Resilience Ratio
Spero Therapeutics Inc asset resilience ratio. Spero Therapeutics Inc (SPRO) has an Asset Resilience Ratio of 0.00% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Spero Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Spero Therapeutics Inc (2017–2022)
Asset resilience ratio of Spero Therapeutics Inc from 2017 to 2022. This chart shows how Spero Therapeutics Inc's Asset Resilience Ratio has changed over time. Read SPRO liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Spero Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Spero Therapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Spero Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Spero Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Spero Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Spero Therapeutics Inc Asset Resilience Ratio by Year (2017–2022)
Spero Therapeutics Inc asset resilience ratio by year from 2017 to 2022. The table below shows the annual Asset Resilience Ratio data for Spero Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.00% | $0.00 | $124.80 Million | -- |
| 2021-12-31 | 19.77% | $33.82 Million | $171.07 Million | -7.40pp |
| 2020-12-31 | 27.17% | $41.70 Million | $153.45 Million | -22.13pp |
| 2019-12-31 | 49.31% | $52.31 Million | $106.10 Million | -13.76pp |
| 2018-12-31 | 63.07% | $81.36 Million | $129.01 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $93.48 Million | -- |
About Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including … Read more